Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Sirius XM Holdings Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while Sirius XM Holdings Inc trades at $30.19 (market cap $10.34B). The key difference: Sirius XM Holdings Inc is far larger — about 2.3× ACADIA Pharmaceuticals Inc.'s market cap, and Sirius XM Holdings Inc pays a 3.52% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | SIRI | |
|---|---|---|
Market Cap | $4.49B | $10.34B |
Sector | Health | Media |
52-Week High | $28.06 | $30.75 |
52-Week Low | $20.06 | $19.92 |
Enterprise Value | $3.69B | $20.01B |
Dividend Yield | — | 3.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Sirius XM (SIRI) trades at $30.71, up 0.66% on the day, with a bullish technical signal from moving averages. The stock shows solid fundamentals with a P/E of 13.03 and a net income margin of 9.86%, supported by recent earnings beats. Analysts maintain a consensus Buy rating with a $31.17 price target, and the company continues to generate strong operating cash flow of $1.90B in 2025. Recent news highlights a new advertising partnership with Alphabet and upcoming Q2 2026 earnings.
The outlook for SIRI is positive, driven by consistent earnings performance and strategic partnerships. Key opportunities include dividend yield and potential index inclusion benefits. Risks involve high debt levels and competitive pressures in the media sector. The stock's current price near the consensus target suggests limited upside unless earnings exceed expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
